Anvisa Reviews Elevidys, a R$20 Million Gene Therapy Suspended in Brazil
Brazil’s health regulator is waiting for additional safety and efficacy data from Roche before deciding whether the treatment can return to the market.
Brazil’s health regulator is waiting for additional safety and efficacy data from Roche before deciding whether the treatment can return to the market.
Regulatory gaps in Brazil’s drug market highlight growing risks in safety, compliance, and institutional credibility.
Regulatory overhaul broadens administration routes, eases access to THC therapies and marks a milestone for patient treatment.